Press releases

CHEPLAPHARM wins again – For the second time in a row CHEPLAPHARM got awarded as one of the Best Managed Companies in Germany

Greifswald, 05/15/2020 – The family-owned pharmaceutical company CHEPLAPHARM Arzneimittel GmbH got honoured with the highly coveted 'Axia Best Managed...

Read more / pdf

CHEPLAPHARM moves into new building and issues inaugural bond

Almost a year after the topping-out ceremony in March 2019, the extension at the companies headquarters in Greifswald (Ziegelhof) is ready for...

Read more / pdf

CHEPLAPHARM buys the rights for Seroquel® and Seroquel XR® in Europe (excluding the UK) and North America

Greifswald, 01/31/2020 – AstraZeneca and CHEPLAPHARM have agreed to transfer the commercial rights for SEROQUEL® and other related brands for the...

Read more / pdf

CHEPLAPHARM’s successful institutional bond debut: 500 million euros of senior secured notes at 3.500% placed with institutional investors

CHEPLAPHARM Arzneimittel GmbH, a repeat issuer in the long-term loan market with 980 million euros of institutional term loan (“TLB”) outstanding,...

Read more / pdf

CHEPLAPHARM announces pricing of Senior Secured Notes

Cheplapharm has priced €500 million aggregate principal amount of its 3.500% senior secured notes due 2027 (the “Notes”), at an offering price of...

Read more / pdf

CHEPLAPHARM announces offering of Senior Secured Notes

Cheplapharm Arzneimittel GmbH has launched an offering of €400 million aggregate principal amount of senior secured notes due 2027.

Read more / pdf

CHEPLAPHARM strengthens its relationship with AstraZeneca by acquiring the global commercial rights to LOSEC®

AstraZeneca has agreed to sell the global commercial rights - excluding China, Japan, the U.S. and Mexico - to LOSEC® (omeprazole) and associated...

Read more / pdf